{"id":927357,"date":"2026-01-14T09:20:42","date_gmt":"2026-01-14T14:20:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/"},"modified":"2026-01-14T09:20:42","modified_gmt":"2026-01-14T14:20:42","slug":"senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/","title":{"rendered":"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Access the segment\u00a0<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5RDqKY3DwgpIdsrF7DbisCvM1og_oALqOFi5qs6JIptOu7B_BaVc3EV9AGovvFMS_HKSlYmod1RPns7VNYDjPtfnLD8MqrQzDSYeB3XesRs=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>here<\/em><br \/>\n        <\/a>\n      <\/p>\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Jan.  14, 2026  (GLOBE NEWSWIRE) &#8212; Senti Biosciences, Inc. (Nasdaq: SNTI) (\u201cSenti Bio\u201d), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=76i-yhAh8UgDHgkJkRdVQDQX5bfg0RYti_TiYh6rAkbevIIILVnlurY0AqsMgt6-YATHVRIfmsblTNEGFlQ5-KVad9TnJQPy-aV5u_V5jEIETWAAsffatecIjdZqMgia3J0RYpBPshD8DaJ7S-ST-Q==\" rel=\"nofollow\" target=\"_blank\">Virtual Investor CEO Connect Segment<\/a>.<\/p>\n<p align=\"justify\">As part of the segment, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UUlyTjzge8MtEJCACBOZ9dsmOYhjCMlJvyYtY6wo67x8wmGLBLcTf9pEaQP4GgclMxM4COFRwvsVugKFsLGX3th1eWuCMEffXrP1mAp4yeXxkExa2jngFLP7RDNTf61Q\" rel=\"nofollow\" target=\"_blank\">Timothy Lu, MD, PhD, CEO<\/a> of Senti, discussed its <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tWtaQIN5Y9wekLZwDuM6Ysi-ak0tKEVADnJ7tebKx7wM1HKDC9PRnHrJNAcjs0YDBGe4nVQMhm69zGLF3k2wMYiA5OV03oDSYqakzYgBUUIlX910EJeo118n9IWvM3Nl2avWwViAjLCrH-j8XCX3A-yUJZahUQD08mX2DEirCtbQ9aUy7HXWvWNTh_Mva51erHge-U9zN6Gs8zRDb7Jum_-XhXRTyRLa-9PCIfo2IGA=\" rel=\"nofollow\" target=\"_blank\">recent news release<\/a> announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company\u2019s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed\/refractory hematologic malignancies, including AML. The RMAT designation builds on the Orphan Drug Designation that the FDA granted SENTI-202 in June. Dr. Lu also discussed the new data from 20 patients (18 with evaluable responses) in its ongoing multinational, multicenter clinical trial of SENTI-202 in patients with relapsed or refractory AML that were recently presented at the American Society of Hematology (ASH) Annual Meeting in Orlando.<\/p>\n<p align=\"justify\">\n        <strong>About Senti Bio<\/strong><br \/>\n        <br \/>Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and\/or to be controllable even after administration. The Company\u2019s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti\u2019s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.<\/p>\n<p align=\"justify\">\n        <strong>Availability of Other Information About Senti Bio<\/strong><br \/>\n        <br \/>For more information, please visit the Senti Bio website at https:\/\/www.sentibio.com or follow Senti Bio on X (formerly Twitter) (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FNsQm89sBxzU8pBbjmhBDkyBBSrEEjUDKl6YAUkQBsdy0VlmAawiBtL_6L3ar6PiTdXtOqFanpXWd43eXpq6a-r3jpLsnArlxIFl5NOuuoH1RCgKbedHlxTIZmTSkZzg05pAqY-_lYltDI8F9a5qBCFPzbvJwGyHknoNCzhkab-bvTfYlYIlUvfYo8F69iI8i8Wk0jcg9EqlpYnJIV0u5TFCpbnsRmA2Cyqt9maVav8=\" rel=\"nofollow\" target=\"_blank\">@SentiBio<\/a>) and LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TMqmKTWK-fX39Wi6_nbDKosRKudRxzOFje4RhrgydvBRqHfTEITc-WGSkTpUWFwa7CtQav15mDI9a0iLd6aqEqljOHEyIfdgD5YNPijGcXUAg-i7iLt0nVjEmZhcT7cZJPYZK3x1PDk9_cxr1lDnyVQZ4a2vYaGWc3lUxZIyxr8vfkvvkX_FaDsYAdP6LbOJX8uDNAIe1HuLd60ZfEyvVSRcKLG2sVwbqnZdOIsXdQ2jZjNcwN7WVWuqmEl2zG_kgq0eel9DzaFFqMemcX4Et64x9wMh_7Q9R8slT0kbX68=\" rel=\"nofollow\" target=\"_blank\">Senti Biosciences<\/a>). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.<\/p>\n<p>\n        <strong>Senti Bio Contacts:<\/strong><br \/>\n        <br \/>Investors: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7-MxCs2fi-9rOWuQHcfPV2YhIpfGOeC5Oj3I0k2aAaSS9gPsKxBhB2A2cPXB3mgnYHcg9W3rRhCi-4Mg4Lakl6DuQ_cECrhA5zmXNfwhhRU=\" rel=\"nofollow\" target=\"_blank\">investors@sentibio.com<\/a><br \/>Media: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=stwS7UbGqrvwTRbxSsOKRsHWWgMPE7oDrwr4CNiNMrbHFJWEOXOvLmKwRYx6EHiUILfo8DGtWWzkzo-N0ht-WIyprcJfn2LpM8HtqgHw-B8=\" rel=\"nofollow\" target=\"_blank\">media@sentibio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Jenene Thomas<br \/>Chief Executive Officer<br \/>JTC Team, LLC<br \/>T: 908.824.0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4wgKe6fZdcV2mR9XQYlLf8mikzbe_-BmnTJR3rm-br1iLEDqtD6Ip_1p8-1LVsbqmFLNXzXxeFxa2mxunIMdfg==\" rel=\"nofollow\" target=\"_blank\">snti@jtcir.com<\/a>\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2U3MTUxOWEtZTY5MC00OTE0LTk3YzItODA1MWU2ODI0YTA4LTEyMjE0NDAtMjAyNi0wMS0xNC1lbg==\/tiny\/Senti-Biosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Access the segment\u00a0 here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) &#8212; Senti Biosciences, Inc. (Nasdaq: SNTI) (\u201cSenti Bio\u201d), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company\u2019s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed\/refractory hematologic malignancies, including AML. The RMAT designation builds on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-927357","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Access the segment\u00a0 here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) &#8212; Senti Biosciences, Inc. (Nasdaq: SNTI) (\u201cSenti Bio\u201d), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company\u2019s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed\/refractory hematologic malignancies, including AML. The RMAT designation builds on the &hellip; Continue reading &quot;Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T14:20:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation\",\"datePublished\":\"2026-01-14T14:20:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/\"},\"wordCount\":520,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/\",\"name\":\"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=\",\"datePublished\":\"2026-01-14T14:20:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/","og_locale":"en_US","og_type":"article","og_title":"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - Market Newsdesk","og_description":"Access the segment\u00a0 here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) &#8212; Senti Biosciences, Inc. (Nasdaq: SNTI) (\u201cSenti Bio\u201d), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company\u2019s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed\/refractory hematologic malignancies, including AML. The RMAT designation builds on the &hellip; Continue reading \"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-14T14:20:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation","datePublished":"2026-01-14T14:20:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/"},"wordCount":520,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/","name":"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=","datePublished":"2026-01-14T14:20:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTIxOSM3MzU5OTYxIzIyMDk4ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senti-biosciences-participates-in-virtual-investor-ceo-connect-segment-to-discuss-the-companys-groundbreaking-aml-data-at-the-american-society-of-hematology-annual-meeting-and-recently-grante\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company\u2019s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=927357"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927357\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=927357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=927357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=927357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}